Picard Medical, Inc. IPO - What You Need to Know

Thinking about jumping into the Picard Medical IPO? It is exciting to get in on the ground floor, but let’s break down what this company actually does before you invest.

Here is the "friend-to-friend" guide to the Picard Medical IPO.

1. What does this company actually do?

Picard Medical owns "SynCardia," which makes the only FDA-approved Total Artificial Heart in the U.S. and Canada. This device replaces both sides of a failing heart. It acts as a "bridge to transplant," keeping patients alive while they wait for a donor. They have supported over 2,100 implants worldwide.

They are also developing the "Emperor TAH." This next-generation device will be fully implantable, removing the need for the external pumps patients currently carry. They aim to launch this by 2028.

2. How do they make money and are they growing?

They make money by selling the SynCardia system, including the heart, surgical tools, and the portable drivers that power the device.

• The Financial Picture: The company is in "survival mode." They currently lose money and spend more cash than they bring in. They rely on borrowing money and selling more shares to stay afloat. They are currently behind on debt payments due in 2026 and are negotiating with lenders to avoid bankruptcy.
• The Strategy: They hope to grow by expanding into China and launching the "Unicorn" driver. This new driver will be smaller and quieter than the current version, with a target launch in 2027.

3. Does the technology actually work?

Recent data is encouraging. Patients using the SynCardia heart have a one-year survival rate between 75% and 86.6%. Serious issues, like strokes, happen in about 5% of cases.

Picard has a competitive edge because of its long history. They have over 30 years of clinical use, while competitors are still in early testing stages. Their manufacturing facility is also fully certified, giving them a proven track record that newer companies lack.

4. What are the main risks?

• Dilution: The company has many outstanding warrants and notes. When these are converted into stock, the company issues more shares. This reduces your percentage of ownership in the company.
• Cash Burn: Expenses consistently exceed profit. Without more sales or new funding, they may run out of money to finish their research or pay their debts.
• Regulatory Hurdles: The business depends entirely on FDA approval. Expanding into China is a complex, multi-year process that may require expensive new clinical trials.
• Debt Issues: Because they are in default on their debt, lenders could demand immediate repayment. This puts the company’s future at serious risk.

5. The "Need to Know" Details

• Ticker Symbol: PMI (on the NYSE American).
• Volatility: This is not a "set it and forget it" stock. Because of their debt problems and complex financing, the stock price will likely swing wildly. Expect big price changes based on news about their debt, clinical trials, or new funding.

Final Thought: Is this for you?

Investing in a company that is currently in default on its debt is a high-stakes move. While the technology is life-saving and proven, the financial health of the company is fragile. If you decide to move forward, keep your position size small and be prepared for significant volatility.

Disclaimer: I am an AI, not a financial advisor. IPOs are high-risk and volatile. Never invest money you cannot afford to lose, and always read the official "Prospectus" on the SEC website before making any final decisions.